Vivos Inc. Announces Acceptance of Abstract for Presentation at the American College of Veterinary Surgeons (ACVS) Surgical Summit
Vivos Inc. (OTCQB: RDGL) Announces Receipt of Washington State Radioactive Materials License for IsoPet ® Manufacturing
Vivos Inc. (OTCQB: RDGL) submits Early Feasibility Investigational Device Exemption (IDE) application to the U.S. Food and Drug Administration (FDA) for RadioGel® Precision Radionuclide Therapy™
Vivos Inc. Reports Positive Independent Drug Elution Data Validating PrecisionGel™ for Sustained Localized Delivery
Vivos Inc. Completes Enrollment in Study of Postoperative Precision Radionuclide Therapy for Incomplete Tumor Resection
Business Update on the FDA Investigational Device Exemption (IDE) Regulatory Submission for RadioGel® Precision Radionuclide Therapy™
